← Drug database

Pemetrexed Lilly (pemetrexed)

Generic
Region
🇪🇺 EU
Active substance
pemetrexed
Company
Eli Lilly Netherlands
Status
Withdrawn
Therapeutic area
Carcinoma, Non-Small-Cell Lung; Mesothelioma
EU approval
Mon 14 Sep 2015
Designations
Generic
Application
EMEA/H/C/004114
ATC
L01BA04
Official record
www.ema.europa.eu

Indication

Malignant pleural mesothelioma Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Pemetrexed Lilly

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.